PRCT
PROCEPT BioRobotics Corporation
NASDAQ · Healthcare · Medical - Devices · US
$22.76
+6.50%Year over year
Reported trailing growth
- Revenue
- +22.7%
- EBITDA
- -33.0%
- EBIT
- -24.5%
- EPS
- -25.2%
- Free cash flow
- -41.1%
- Operating cash flow
- -35.2%
Forward estimates
Based on analyst estimates
- Revenue
- +29.8%
- EBITDA
- +35.7%
- EPS
- +29.8%
Three-year CAGR
- Revenue
- +60.1%
- EBITDA
- -4.2%
- EBIT
- -7.5%
- Net income
- -4.5%
- EPS
- +1.7%
- Free cash flow
- +43.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026